Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GCS 100

Drug Profile

GCS 100

Alternative Names: GBC-590; GCS-100; GCS-100LE; LJPC-101; NCCG

Latest Information Update: 02 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Barbara Ann Karmanos Cancer Institute; Wayne State University
  • Developer GlycoGenesys; La Jolla Pharmaceutical Company; Prospect Therapeutics
  • Class Antineoplastics; Polysaccharides
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Cell adhesion molecule inhibitors; Galectin 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Cancer; Chronic lymphocytic leukaemia; Colorectal cancer; Diffuse large B cell lymphoma; Liver disorders; Multiple myeloma; Pancreatic cancer; Prostate cancer; Renal failure

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Jun 2016 La Jolla Pharmaceutical completes the phase II GCS-100-CS-4003 extension trial for Renal failure (chronic kidney disease) in USA (NCT02155673)
  • 08 May 2015 GCS 100 is available for licensing as of 08 May 2015. www.ljpc.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top